Physician profile
Michael Louis
NPI 1851825145
$3,003.29
in general payments reported to CMS, 2019-2025
20 companies · $214 in 2025
The $214 reported for 2025 was less than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $382 · 2020: $199 · 2021: $377 · 2022: $689 · 2023: $779 · 2024: $364 · 2025: $214.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,357.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,357.40 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $916.89 | 2019-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $303.54 | 2021-2023 | Entyvio |
| Gilead Sciences, INC. | $245.42 | 2019-2020 | |
| Janssen Biotech, INC. | $193.61 | 2025 | Tremfya |
| Nestle Healthcare Nutrition INC. | $175.23 | 2021-2023 | |
| Regeneron Healthcare Solutions, INC. | $166.48 | 2023 | Dupixent |
| Ardelyx, INC. | $150.00 | 2023 | Ibsrela |
| Steris Corporation | $141.55 | 2024 | |
| Daiichi Sankyo INC. | $124.55 | 2021 | |
| Evoke Pharma, INC. | $121.94 | 2023 | Gimoti |
| Allergan, INC. | $94.95 | 2019 | |
| Genzyme Corporation | $80.85 | 2021 | |
| Vivus LLC | $71.04 | 2022-2023 | Pancreaze |
| Napo Pharmaceuticals INC | $63.18 | 2019 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $37.24 | 2020-2022 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $35.15 | 2022 | |
| Lilly USA, LLC | $23.66 | 2020 | |
| Ironwood Pharmaceuticals, INC | $22.21 | 2022 | |
| Fresenius Kabi USA, LLC | $18.35 | 2023 | |
| Medtronic, INC. | $17.45 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Louis listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.